397 related articles for article (PubMed ID: 33060124)
1. Targeting the gut-liver-immune axis to treat cirrhosis.
Tranah TH; Edwards LA; Schnabl B; Shawcross DL
Gut; 2021 May; 70(5):982-994. PubMed ID: 33060124
[TBL] [Abstract][Full Text] [Related]
2. Gut-liver axis signaling in portal hypertension.
Simbrunner B; Mandorfer M; Trauner M; Reiberger T
World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.
Muñoz L; Borrero MJ; Úbeda M; Conde E; Del Campo R; Rodríguez-Serrano M; Lario M; Sánchez-Díaz AM; Pastor O; Díaz D; García-Bermejo L; Monserrat J; Álvarez-Mon M; Albillos A
Hepatology; 2019 Sep; 70(3):925-938. PubMed ID: 30414342
[TBL] [Abstract][Full Text] [Related]
4. Potential mechanisms linking gut microbiota and portal hypertension.
Baffy G
Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
[TBL] [Abstract][Full Text] [Related]
5. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
[TBL] [Abstract][Full Text] [Related]
6. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
[TBL] [Abstract][Full Text] [Related]
7. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota-related complications in cirrhosis.
Gómez-Hurtado I; Such J; Sanz Y; Francés R
World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of microbiome in patients with decompensated cirrhosis.
Oikonomou T; Papatheodoridis GV; Samarkos M; Goulis I; Cholongitas E
World J Gastroenterol; 2018 Sep; 24(34):3813-3820. PubMed ID: 30228776
[TBL] [Abstract][Full Text] [Related]
10. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
Albillos A; de Gottardi A; Rescigno M
J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
Chopyk DM; Grakoui A
Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
[TBL] [Abstract][Full Text] [Related]
12. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.
Pierantonelli I; Rychlicki C; Agostinelli L; Giordano DM; Gaggini M; Fraumene C; Saponaro C; Manghina V; Sartini L; Mingarelli E; Pinto C; Buzzigoli E; Trozzi L; Giordano A; Marzioni M; Minicis S; Uzzau S; Cinti S; Gastaldelli A; Svegliati-Baroni G
Sci Rep; 2017 Sep; 7(1):12200. PubMed ID: 28939830
[TBL] [Abstract][Full Text] [Related]
13. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
15. Alcoholic liver disease: the gut microbiome and liver cross talk.
Hartmann P; Seebauer CT; Schnabl B
Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
[TBL] [Abstract][Full Text] [Related]
16. Microbiota, cirrhosis, and the emerging oral-gut-liver axis.
Acharya C; Sahingur SE; Bajaj JS
JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978799
[TBL] [Abstract][Full Text] [Related]
17. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
18. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
Stecher B
Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
[TBL] [Abstract][Full Text] [Related]
19. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.
Chen D; Le TH; Shahidipour H; Read SA; Ahlenstiel G
Cells; 2019 Oct; 8(11):. PubMed ID: 31717860
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota changes and chronic hepatitis C virus infection.
Preveden T; Scarpellini E; Milić N; Luzza F; Abenavoli L
Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):813-819. PubMed ID: 28621554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
